Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Vertex To Acquire ViroChem Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Vertex To Acquire ViroChem Pharma

Vertex Pharmaceuticals has entered a definitive agreement to acquire ViroChem Pharma in a stock and cash transaction worth $376 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Vertex Pharmaceuticals has entered a definitive agreement to acquire ViroChem Pharma in a stock and cash transaction worth $376 million. The acquisition adds two polymerase inhibitors to Vertex’s hepatitis C virus (HCV) drug development portfolio, which includes the HCV protease inhibitor telaprevir.

With the addition of these compounds, Vertex will pursue new combinations of Specifically Targeted Antiviral Therapies for hepatitis C (STAT-Cs) for the treatment of HCV infection. ViroChem’s HCV portfolio includes VCH-222 and VCH-759, which have demonstrated substantial reductions in plasma HCV RNA when dosed as single agents and have been well tolerated in clinical studies to date. Vertex expects to begin clinical evaluation of combination regimens of its HCV protease inhibitor telaprevir, currently in Phase III development, in the second half of this year.

“This acquisition significantly strengthens our pipeline in hepatitis C by bringing together Vertex’s telaprevir, our HCV protease inhibitor in registration studies, with the HCV non-nucleoside polymerase inhibitors being developed by ViroChem,” said Joshua Boger, Ph.D., chief executive officer of Vertex. “Through this acquisition, we’re well positioned as a leader in the development of HCV therapies. Our goal is to further advance HCV care for patients through the creation of novel and highly potent STAT-C combination regimens.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics